Now liveThe Skillselion MCP - thousands of ranked skills, loaded into your agent mid-task. No install.Get it →
mims-harvard avatar

Tooluniverse Drug Repurposing

  • 352 installs
  • 1.6k repo stars
  • Updated August 4, 2026
  • mims-harvard/tooluniverse

tooluniverse-drug-repurposing is a Harvard ToolUniverse agent skill that screens approved drugs for new disease indications using target-based, compound-based, and disease-driven strategies with DrugBank, ChEMBL, and Ope

About

tooluniverse-drug-repurposing is an agent skill in mims-harvard/tooluniverse that systematically identifies and ranks drug repurposing candidates using ToolUniverse Python integrations. It defines three core strategies—target-based, compound-based, and disease-driven—and a five-phase workflow covering disease and target analysis, drug discovery, safety assessment, literature evidence, and composite scoring on a 0–100 Repurposing Viability Scale. Developers in computational biology and pharma engineering reach for it when exploring orphan-disease hypotheses, off-label indications, or repositioning approved drugs before wet-lab validation. Key ToolUniverse tools include OpenTargets disease lookups, DrugBank and DGIdb drug-gene queries, ChEMBL bioactivity checks, Reactome pathway enrichment, PubMed literature search, and ClinicalTrials.gov search. The skill stresses dose-feasibility checks because insufficient exposure at the new target is the most common repurposing failure mode.

  • Approved-drug indication scanning
  • Target-disease linkage scoring
  • Agent-guided candidate ranking
  • ToolUniverse repurposing APIs
  • Fast in-silico triage workflows

Tooluniverse Drug Repurposing by the numbers

  • 352 all-time installs (skills.sh)
  • +6 installs in the week ending Aug 4, 2026 (Skillselion tracking)
  • Ranked #540 of 2,064 Data Science & ML skills by installs in the Skillselion catalog
  • Data as of Aug 5, 2026 (Skillselion catalog sync)
npx skills add https://github.com/mims-harvard/tooluniverse --skill tooluniverse-drug-repurposing

Add your badge

Show developers this skill is listed on Skillselion. Paste this into your README.

Listed on Skillselion
Installs352
repo stars1.6k
Last updatedAugust 4, 2026
Repositorymims-harvard/tooluniverse

How do you screen drugs for repurposing candidates computationally?

Screen approved drugs against new indications using ToolUniverse repurposing tools to rank candidates before preclinical or computational follow-up.

Who is it for?

Computational biology and bioinformatics developers building agent workflows that query ToolUniverse for drug repurposing hypotheses.

Skip if: General application developers without biomedical data needs who do not run ToolUniverse Python pipelines or drug-database integrations.

When should I use this skill?

A developer asks to find repurposing candidates for a disease, rank approved drugs for a new indication, or run ToolUniverse drug-target feasibility checks.

What you get

Ranked repurposing candidate list, viability scores, literature evidence grades, and dose-feasibility assessments

  • ranked candidate report
  • viability score table
  • literature evidence summary

By the numbers

  • Defines 3 core repurposing strategies in SKILL.md
  • Uses a 5-phase workflow from disease analysis through scoring and ranking
  • Scores candidates on a 0–100 Repurposing Viability Scale

Files

SKILL.mdMarkdownGitHub ↗

Drug Repurposing with ToolUniverse

Systematically identify and evaluate drug repurposing candidates using multiple computational strategies.

IMPORTANT: Always use English terms in tool calls. Respond in the user's language.

---

Reasoning Before Searching

Start by asking: WHY might this drug work for a new disease? Three strategies:

  • (a) Same target: The drug's primary target is also involved in the new disease. This is the strongest hypothesis — use OpenTargets to check if the target has genetic evidence in both diseases before any other search.
  • (b) Off-target activity: The drug has secondary targets or off-target effects that are relevant to the new disease. Check ChEMBL bioactivity data for all known targets of the drug, not just its primary one.
  • (c) Shared pathways: The original indication and new disease share molecular pathways, even if the target itself is not genetically linked. Use Reactome and STRING to compare pathway overlap between diseases.

Each strategy uses different tools and has different evidentiary weight. Identify which strategy applies FIRST, then choose the corresponding workflow below. Do not run all three strategies blindly — reason about which is most plausible given the drug's mechanism.

LOOK UP DON'T GUESS: Never assume a drug hits a target, never assume a target is disease-relevant, never assume pathway overlap. Verify each link with tool calls.

Core Strategies

1. Target-Based: Disease targets -> Find drugs that modulate those targets 2. Compound-Based: Approved drugs -> Find new disease indications 3. Disease-Driven: Disease -> Targets -> Match to existing drugs

---

Workflow Overview

Phase 1: Disease & Target Analysis
  Get disease info (OpenTargets), find associated targets, get target details

Phase 2: Drug Discovery
  Search DrugBank, DGIdb, ChEMBL for drugs targeting disease-associated genes
  Get drug details, indications, pharmacology

Phase 3: Safety & Feasibility Assessment
  FDA warnings, FAERS adverse events, drug interactions, ADMET predictions

Phase 4: Literature Evidence
  PubMed, Europe PMC, clinical trials for existing evidence

Phase 5: Scoring & Ranking
  Composite score: target association + safety + literature + drug properties

See: PROCEDURES.md for detailed step-by-step procedures and code patterns.

---

Quick Start

from tooluniverse import ToolUniverse
tu = ToolUniverse()
tu.load_tools()

# Step 1: Get disease targets
disease_info = tu.tools.OpenTargets_get_disease_id_description_by_name(diseaseName="rheumatoid arthritis")
# Response nests ID at data.search.hits[0].id
disease_id = disease_info['data']['search']['hits'][0]['id']
targets = tu.tools.OpenTargets_get_associated_targets_by_disease_efoId(efoId=disease_id, limit=10)

# Step 2: Find drugs for each target
# Response nests targets at data.disease.associatedTargets.rows
rows = targets['data']['disease']['associatedTargets']['rows']
for target in rows[:5]:
    gene = target['target']['approvedSymbol']
    drugs = tu.tools.DGIdb_get_drug_gene_interactions(genes=[gene])

---

Key ToolUniverse Tools

Disease & Target:

  • OpenTargets_get_disease_id_description_by_name - Disease lookup
  • OpenTargets_get_associated_targets_by_disease_efoId - Disease targets
  • UniProt_get_entry_by_accession - Protein details

Drug Discovery:

  • drugbank_get_drug_name_and_description_by_target_name - Drugs by target. Param: `query=` (NOT `target_name=`)
  • drugbank_get_drug_name_and_description_by_indication - Drugs by indication. Param: `query=` (NOT `indication=`)
  • DGIdb_get_drug_gene_interactions - Drug-gene interactions. Response path: data.data.genes.nodes[0].interactions
  • ChEMBL_search_drugs / ChEMBL_get_drug_mechanisms - Drug search and MOA

Drug Information (ALL DrugBank tools use query= as the search parameter, plus case_sensitive=False, exact_match=False, limit=N):

  • drugbank_get_drug_basic_info_by_drug_name_or_id - Basic info. Param: `query="drug_name"`
  • drugbank_get_indications_by_drug_name_or_drugbank_id - Approved indications. Param: `query="drug_name"`
  • drugbank_get_pharmacology_by_drug_name_or_drugbank_id - Pharmacology. Param: `query="drug_name"`
  • drugbank_get_targets_by_drug_name_or_drugbank_id - Drug targets. Param: `query="drug_name"`

Safety:

  • FDA_get_warnings_and_cautions_by_drug_name - FDA warnings
  • FAERS_search_reports_by_drug_and_reaction - Adverse events. Param: `medicinalproduct=` (NOT `drug_name=`)
  • FAERS_count_death_related_by_drug - Serious outcomes. Param: `medicinalproduct=` (NOT `drug_name=`)
  • drugbank_get_drug_interactions_by_drug_name_or_id - Interactions

Property Prediction:

  • ADMETAI_predict_physicochemical_properties / ADMETAI_predict_toxicity - ADMET and toxicity

Pathway & Network Analysis:

  • ReactomeAnalysis_pathway_enrichment - Pathway enrichment. Param: `identifiers="SOD1\nTARDBP\nFUS"` (newline-separated string, NOT array)
  • STRING_get_network - Protein interaction networks. Param: `identifiers="SOD1\rTARDBP\rFUS"` (CR-separated string), `species=9606`
  • CTD_get_gene_diseases - Curated gene-disease associations. Param: `input_terms="gene_symbol"` (NOT `gene_symbol=`)

Literature & Clinical Trials:

  • PubMed_search_articles / EuropePMC_search_articles - Literature search
  • search_clinical_trials - ClinicalTrials.gov search. Use condition for disease name. The intervention filter is strict and may miss trials — use query_term for broader drug-name matching as fallback.
CNS diseases note: For neurological indications (ALS, Alzheimer's, Parkinson's), prioritize BBB-penetrant candidates. Use ChEMBL molecular properties (MW < 500, PSA < 90) as BBB proxy since ADMETAI_predict_BBB_penetrance may require the tooluniverse[ml] extra. Consider route of administration (oral preferred for patients with swallowing difficulty) and sex-specific effects from preclinical models.

---

Scoring & Decision Framework

Repurposing Viability Score (0-100)

CategoryPointsHow to Score
Target Association0-4040: Target has genetic evidence in disease (GWAS, rare variants); 25: Target is in a disease-associated pathway (Reactome, KEGG); 15: Target is differentially expressed in disease tissue; 5: Target shares a GO term with disease genes
Safety Profile0-3030: FDA-approved drug, no black box warning, established safety record; 20: FDA-approved with manageable warnings; 10: Phase II+ data, acceptable safety; 0: Preclinical only or serious safety signals
Literature Evidence0-2020: Phase II+ trial for the new indication exists; 15: Case reports or retrospective studies show efficacy; 10: Preclinical in-vivo evidence (animal models); 5: In-vitro evidence only; 0: No prior evidence
Drug Properties0-1010: Oral, good bioavailability, IP available; 5: Injectable or narrow therapeutic window; 0: Poor PK or formulation challenges

Classification:

  • 80-100: Strong candidate — proceed to clinical evaluation
  • 60-79: Promising — worth preclinical validation or retrospective study
  • 40-59: Speculative — needs significant additional evidence
  • <40: Weak — likely not worth pursuing without new mechanistic insight

Evidence Grading for Repurposing

GradeDefinitionAction
E1 (Clinical)Existing clinical trial for new indication (any phase)High priority — check trial results
E2 (Epidemiological)Retrospective/observational data showing benefitModerate priority — design prospective study
E3 (Preclinical)Animal model evidence for new indicationStandard priority — validate mechanism
E4 (Computational)Target overlap, network proximity, or molecular similarity onlyLow priority — needs experimental validation

How to Interpret and Combine Results

After running Phases 1-4, synthesize by answering:

1. Is the target validated for this disease? Check OpenTargets association score (>0.5 = strong). Cross-reference with genetic evidence (GWAS hits, rare variant studies). If target association is only pathway-level, the repurposing hypothesis is speculative.

2. Does the drug actually hit the target at achievable doses? Check ChEMBL IC50/Ki values. If the drug's affinity for the new target is >10x weaker than for its original target, clinical efficacy is unlikely at safe doses.

3. What's the safety margin? Compare the dose needed for the new indication to the approved dose. If higher doses are needed, safety data from the original indication may not apply.

4. Is there prior clinical evidence? A Phase II trial for the new indication (even failed) is more informative than 100 computational predictions. Check search_clinical_trials first.

5. What's the competitive landscape? If better drugs already exist for the disease, repurposing offers little value. Check DrugBank indications for approved therapies.

---

Best Practices

1. Check clinical trials FIRST: search_clinical_trials(condition="[disease]", intervention="[drug]") — if a trial already exists, start there 2. Validate targets with genetics: Genetic evidence (GWAS, rare variants) is the strongest predictor of successful drug development 3. Safety first: Prioritize approved drugs with known safety profiles 4. Dose matters: A drug that hits a disease target at 100x its approved dose is not a repurposing candidate 5. Mechanism over correlation: Network proximity alone is insufficient — explain WHY the drug should work 6. Consider IP and formulation: Generic drugs are easier to repurpose but harder to fund trials for

Computational Procedure: Drug-Target Dose Feasibility Check

A drug that hits a new target only at 100x its approved dose is NOT a viable repurposing candidate. Use this procedure after identifying drug-target pairs:

# Drug-target dose feasibility analysis
# Uses ChEMBL bioactivity data from ToolUniverse
from tooluniverse import ToolUniverse

tu = ToolUniverse()
tu.load_tools()

def check_dose_feasibility(drug_name, original_target, new_target):
    """
    Compare drug's potency at original vs new target.
    If new_target IC50 > 10x original_target IC50, flag as unlikely feasible.
    """
    # Get bioactivity for original target
    orig = tu.run_one_function({
        'name': 'ChEMBL_get_bioactivities',
        'arguments': {
            'molecule_chembl_id': drug_name,  # or search first
            'target_chembl_id': original_target,
            'limit': 10
        }
    })

    # Get bioactivity for new target
    new = tu.run_one_function({
        'name': 'ChEMBL_get_bioactivities',
        'arguments': {
            'molecule_chembl_id': drug_name,
            'target_chembl_id': new_target,
            'limit': 10
        }
    })

    # Extract IC50/Ki values and compare
    # If new target requires >10x concentration → NOT FEASIBLE at safe doses
    # If new target is within 3x → PROMISING
    # If new target is within 1x → STRONG candidate
    pass  # Parse actual values from results

# Alternative: Quick Cmax check
# If published Cmax at approved dose < IC50 for new target → NOT FEASIBLE
# Cmax data can be found in:
#   - DrugBank pharmacology section
#   - DailyMed clinical pharmacology section
#   - PubMed PK studies

Key principle: The most common reason repurposing fails is insufficient drug exposure at the new target. Always check whether the drug's concentration at approved doses reaches the IC50 for the new target.

---

Troubleshooting

ProblemSolution
Disease not foundTry synonyms or EFO ID lookup
No drugs for targetCheck HUGO nomenclature, expand to pathway-level, try similar targets
Insufficient literatureSearch drug class instead, check preclinical/animal studies
Safety data unavailableDrug may not be US-approved, check EMA or clinical trial safety

---

Reference Files

  • REFERENCE.md - Detailed reference documentation
  • EXAMPLES.md - Sample repurposing analyses
  • PROCEDURES.md - Step-by-step procedures with code
  • REPORT_TEMPLATE.md - Output report template
  • Related skills: disease-intelligence-gatherer, chemical-compound-retrieval, tooluniverse-sdk

Related skills

FAQ

What strategies does tooluniverse-drug-repurposing use?

tooluniverse-drug-repurposing uses three strategies: target-based repurposing from disease targets, compound-based search from approved drugs, and disease-driven discovery through associated genes. Each strategy maps to different ToolUniverse API calls.

How does tooluniverse-drug-repurposing score candidates?

tooluniverse-drug-repurposing applies a 0–100 Repurposing Viability Score across target association, safety profile, literature evidence, and drug properties. Scores of 80–100 indicate strong candidates worth clinical evaluation per the skill framework.

Data Science & MLagentsresearchautomation

This week in AI coding

Five minutes, every Monday - the tools, releases and tactics for developers.

unsubscribe anytime.